Division of Genetic Medicine and Clinical Pharmacology Archive — Page 5 of 12
-
November 10, 2023
After 40 years, genetics still surprises VUMC’s Nancy Cox
As she looks back on her 40-plus year career, what surprises Nancy Cox, PhD, an internationally known geneticist at Vanderbilt University Medical Center, is how much progress has been made, and yet how much more there is to learn about the role genetic variation plays in human disease. -
October 31, 2023
Polygenic ‘scores’ may improve cancer screening
Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found. -
October 25, 2023
Study to explore link between salt taste sensitivity and salt intake, hypertension and genetic variations in individuals of African descent
A new study will explore the link between salt taste sensitivity and salt intake, blood pressure, hypertension, and genetic variations in individuals of African descent. -
October 5, 2023
Kidney disease gene also has a protective mutation
African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk. -
October 3, 2023
Research fellowship for genetic counselors established at Vanderbilt
Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine. -
July 26, 2023
Nancy Cox receives American Society of Human Genetics Leadership Award
Nancy Cox, PhD, director of the Vanderbilt Genetics Institute, is the recipient of the 2023 ASHG Leadership Award from the American Society of Human Genetics. -
July 25, 2023
Signaling pathways in liposarcomas
A broad bioinformatics approach revealed that Hedgehog signaling is upregulated in dedifferentiated liposarcoma, suggesting this pathway may be an early indicator of poor prognosis and a potential therapeutic target.